GE-RENEWABLE-ENERGY
13.2.2020 10:02:09 CET | Business Wire | Press release
GE Renewable Energy’s Grid Solutions business (NYSE-GE) has been awarded €2.2 million through the European Commission’s LIFE climate action program to help fund the development of a sulfur hexafluoride (SF6 )-free, 420 kiloVolt (kV) 63 kilo Amps (kA) gas-insulated substation (GIS) circuit-breaker.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005296/en/
The new circuit-breaker will rely on GE’s industry-leading “Green Gas for Grid”—or “g3” (pronounced “g- cubed”)—technology, resulting in the same high performance and compact size as a traditional SF6 -insulated circuit-breaker, but with a gas mass having more than a 99% reduced CO₂ equivalent value. Upon completion in 2022, the g3 circuit-breaker is expected to be the first SF6 -free 420 kV gas-insulated substation circuit-breaker in the world.
A circuit-breaker is protective equipment used to cut power in case of a problem on the grid. High-voltage 420-kV circuit-breakers are found at electrical substations on long-distance transmission networks.
Due to its strong insulating and arc-quenching properties, SF6 is widely used in substation equipment with the transmission industry accounting for approximately 80% of the world’s usage. Identified as the world’s most potent greenhouse gas by the 1997 Kyoto Protocol, SF6 is estimated to contribute 23,500 times more emissions than CO₂ if leaked and can remain in the atmosphere for up to 3,200 years.
“Our g3 technology is a game-changing alternative to SF6 for high-voltage equipment and is part of GE’s broader efforts to help the electric transmission and distribution industry reduce its greenhouse gas emissions,” said Vera Silva, Chief Technology Officer at GE’s Grid Solutions.
“Because 420 kV is the highest voltage level used in most European countries, a proven g3 –insulated 420 kV circuit-breaker will demonstrate that g3 technology can be applied to other high-voltage levels, as well as all other gas-insulated substation components, such as disconnectors, earthing switches, voltage transformers,” said Yannick Kieffel, Grid Solutions’ Materials and Eco Design Team Leader and Project Leader for the EU-funded g3 project.
Currently, GE offers the following g3 products: live tank circuit-breakers and gas-insulated substations up to 145 kV, gas-insulated lines up to 420 kV and instrument transformers up to 245 kV.
“This project is a great fit for our recent round of LIFE financial awards due to its potential impact on Europe’s transition to a more sustainable and low-carbon future,” said Angelo Salsi, LIFE Programme Head of Unit at the Executive Agency for Small and Medium-sized Enterprises (EASME). “The LIFE program is one of the most efficient and well known EU funding mechanisms that has supported nature, the environment and climate action for over 25 years. We look forward to the positive ripple effect this project will have across Europe over the next decade and beyond.”
For the full press release on the g3 EU-funded circuit-breaker project LIFE18 CCM/FR/001096 LIFE GRID , click here .
GE’s Grid Solutions
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. https://www.gegridsolutions.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005296/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom